CAPA Blog

Neonatal Opioid Withdrawal Syndrome and MAT with Methadone and Buprenorphine

FDA (05/26) – Today the U.S. Food and Drug Administration (FDA) is requiring safety labeling changes for methadone and buprenorphine products when used by pregnant women for medication-assisted treatment (MAT) of opioid use disorder to ensure providers have complete information about the benefits and risks of these products. Methadone and buprenorphine can be used for the treatment of pain and/or MAT, which combines medication with counseling and behavioral therapies. MAT plays an important role in treating opioid use disorder. For pregnant women, this treatment may ultimately improve outcomes for them and their babies. Read more

Leave a Reply

Your email address will not be published. Required fields are marked *